



Haemonetics Completes Acquisition of TEG(R) Hemostasis Analyzer Business

November 20, 2007

BRAINTREE, Mass., Nov. 20 /PRNewswire-FirstCall/ -- Haemonetics Corporation, a global blood management company, confirmed today that it has acquired Haemoscope Corporation's TEG(R) Thrombelastograph(R) Hemostasis Analyzer business for \$44 million cash. The companies previously announced their agreement on the acquisition. (See press release of October 30, 2007.)

Chris Lindop, Haemonetics' Chief Financial Officer, noted, "The TEG business acquisition is strategic and strengthens our vision of being a global leader in blood management for our customers. The business expands Haemonetics' product portfolio by providing clinicians with a diagnostic tool to optimize blood management practice."

The TEG business has annual revenues of approximately \$16 million, growing more than 15% annually. Gross margin and operating margin are accretive to Haemonetics' existing business. The acquisition will be neutral to earnings per share in FY08 and accretive in FY09.

The transaction represents Haemonetics' third blood management-related acquisition this year. The Company previously acquired Information Data Management ("IDM"), a software provider to blood banks and testing laboratories, and Infonale, Inc., a provider of blood management consulting services to surgical hospitals.

Haemonetics has posted Frequently Asked Questions on the subject transaction on its website at <http://www.haemonetics.com/site/content/km/factSheet.asp>.

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, IT products, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at <http://www.haemonetics.com>.

This release contains forward looking statements that involve risks and uncertainties, including technological advances in the medical field and standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, product demand, market acceptance, regulatory uncertainties, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates, changes in customers' ordering patterns, the effect of industry consolidation as seen in the plasma market, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate and other risks detailed in the Company's filings with the Securities and Exchange Commission. The foregoing list should not be construed as exhaustive. The forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results and experience could differ materially from the forward-looking statements.

Contact:
Julie Fallon
Tel.(781) 356-9517
Alternate Tel. (617) 320-2401
fallon@haemonetics.com

SOURCE Haemonetics Corporation

-0- 11/20/2007

/CONTACT: Julie Fallon of Haemonetics Corporation, +1-781-356-9517, or
Alternate Tel., +1-617-320-2401, fallon@haemonetics.com /
/Web site: <http://www.haemonetics.com>
<http://www.haemonetics.com/site/content/km/factSheet.asp> /
(HAE)

CO: Haemonetics Corporation; Haemoscope Corporation
ST: Massachusetts
IN: MTC HEA STW CPR
SU: TNM

AM-AB

-- NETU034 --

4379 11/20/2007 16:00 EST <http://www.prnewswire.com>